NCT05222399View on ClinicalTrials.gov

A Study of LY3871801 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions

Healthy

Interventions

DRUG

LY3871801

Administered orally.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY